Victory Capital Management’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-9,512
| Closed | -$569K | – | 3823 |
|
|
2019
Q4 | $569K | Sell |
9,512
-1,105,017
| -99% | -$41.5M | ﹤0.01% | 1952 |
|
|
2019
Q3 | $31.3M | Buy |
1,114,529
+210,308
| +23% | +$7.18M | 0.04% | 629 |
|
|
2019
Q2 | $34.2M | Buy |
904,221
+23,620
| +3% | +$907K | 0.07% | 433 |
|
|
2019
Q1 | $34.4M | Buy |
880,601
+18,040
| +2% | +$517K | 0.08% | 401 |
|
|
2018
Q4 | $18.4M | Buy |
862,561
+101,200
| +13% | +$2.61M | 0.05% | 567 |
|
|
2018
Q3 | $30.1M | Buy |
761,361
+22,120
| +3% | +$825K | 0.06% | 493 |
|
|
2018
Q2 | $28.2M | Buy |
739,241
+191,950
| +35% | +$7.11M | 0.06% | 503 |
|
|
2018
Q1 | $16.4M | Buy |
547,291
+459,617
| +524% | +$15.6M | 0.04% | 636 |
|
|
2017
Q4 | $2.74M | Buy |
87,674
+16,500
| +23% | +$453K | 0.01% | 933 |
|
|
2017
Q3 | $1.99M | Sell |
71,174
-1,850
| -3% | -$40.2K | ﹤0.01% | 989 |
|
|
2017
Q2 | $1.4M | Sell |
73,024
-890
| -1% | -$14.2K | ﹤0.01% | 1082 |
|
|
2017
Q1 | $1.26M | Buy |
73,914
+45,024
| +156% | +$728K | ﹤0.01% | 1085 |
|
|
2016
Q4 | $528K | Sell |
28,890
-7,110
| -20% | -$123K | ﹤0.01% | 1269 |
|
|
2016
Q3 | $641K | Buy |
+36,000
| New | +$546K | ﹤0.01% | 1176 |
|
Victory Capital Management's BOLD Position: Q1 2020 in Review
Victory Capital Management sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 9,512 shares — an estimated $569K sold.
Victory Capital Management first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $34.4M in Q1 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Victory Capital Management reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Victory Capital Management sold 9,512 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $569K.
- Victory Capital Management first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- Victory Capital Management's Audentes Therapeutics, Inc position peaked at $34.4M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Victory Capital Management's 13F filing for Q1 2020, filed 4 May 2020.